Adverse skin reactions following intravitreal bevacizumab injection

Ameen, Sally; Entabi, Molham; Lee, N; Stavrakoglou, Anastasios

doi:10.1136/bcr.02.2010.2753

Cited by 2 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All reported rashes associated with intravitreal bevacizumab have been resolved after discontinuation of the drug. [ 2 3 4 5 ] Similarly, once our patient's bevacizumab was replaced by aflibercept therapy, he had no further cutaneous reactions over 9 months. Physicians administering intravitreal bevacizumab should be aware of this potential cutaneous side effect, its delayed initial presentation, increasing intensity, response to anti-inflammatory medication and its resolution after cessation of bevacizumab.…”

Section: Discussionmentioning

confidence: 78%

“…Our literature review found 5 reports of skin reactions after intravitreal injection of bevacizumab from 2009 to 2016. [ 2 3 4 5 ] These cases revealed 4 skin pathologies: Cutaneous lupus erythematosus, pityriasis rubra pilaris-like eruption, eczematous pruritic plaques and papules, and acneiform lesions.…”

Section: Discussionmentioning

confidence: 99%

“…While one center has seen no significant cutaneous reactions during 10-years of treatment follow-up, several centers have implicated it as a source of cutaneous eruptions, including cutaneous lupus erythematosus, pityriasis rubra pilaris-like eruption, eczematous pruritic plaques and papules, and acneiform lesions. [ 2 3 4 5 6 ]…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cutaneous cell-mediated delayed hypersensitivity to intravitreal bevacizumab

Fam

Finger

2020

Middle East Afr J Ophthalmol

View full text Add to dashboard Cite

The literature contains few reports describing autoimmune reactions to intravitreal bevacizumab and no Type-IV delayed hypersensitivity reactions. This was unexpected, as administration of intravenous bevacizumab has frequently caused dermatologic side-effects. This difference was likely attributable in part to the minimum 300-times difference between intravitreal versus intravenous dosing. Here, we present a case of a 52-year-old male who was treated with plaque brachytherapy for a subfoveal choroidal melanoma. The patient was treated with intravitreal bevacizumab for macular edema, retinal detachment and to delay radiation retinopathy. Following his eighth injection, the patient experienced pruritus, rashes, and progressive exacerbations associated with subsequent injections. Cessation of bevacizumab with or without medication (e.g., oral steroid, antihistamine) resulted in complete remission. Switching to periodic intravitreal aflibercept resulted in no additional cutaneous reactions. Physicians administering intravitreal bevacizumab should be aware of this potential systemic side-effect. Its delayed time course facilitates identification and, thus, treatment to resolution.

show abstract

Section: Discussionmentioning

confidence: 78%